Rating Change
RBC Capital reiterated its Outperform rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on October 08, 2026.
reiterateNASDAQ:RYTM
RBC Capital Reiterates Outperform Rating on Rhythm Pharmaceuticals, Inc. (RYTM)
RBC Capital reiterated its Outperform rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on October 08, 2026.
At publication ·
What changed
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) · reiterate
- Firm
- RBC Capital
- Rating
- Outperform to Outperform
- Price at event
- $89.64
- Market capitalization
- $7.8B
At a glance
Key takeaways
- RBC Capital maintained an Outperform rating on Rhythm Pharmaceuticals (RYTM) on October 8, 2026, with the stock trading at $89.64.
Market Context
Rhythm Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $89.64 with a market capitalization of $7.8B. The stock has declined 14.8% over the past 52 weeks.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rhythm Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rhythm Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Aug 28, 2026 | Deutsche Bank | Hold | N/A |
| Aug 07, 2026 | JP Morgan | Overweight | N/A |
| Aug 05, 2026 | Citizens | Market Outperform | N/A |
| Aug 05, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RYTM Stock Page
Frequently Asked Questions
What does the Outperform rating mean for RYTM?
A rating of Outperform from RBC Capital reflects the analyst's outlook on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RYTM forecast page.